Trials / Terminated
TerminatedNCT04920383
ALPN-202 With PD-1 Inhibition in Advanced Malignancies
An Open-label Study of ALPN-202 Combined With PD-1 Inhibition in Subjects With Advanced Malignancies (NEON-2)
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Alpine Immune Sciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALPN-202 | Various doses |
| DRUG | pembrolizumab KEYTRUDA® | Varies |
Timeline
- Start date
- 2021-06-22
- Primary completion
- 2022-11-08
- Completion
- 2023-02-28
- First posted
- 2021-06-09
- Last updated
- 2024-03-01
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04920383. Inclusion in this directory is not an endorsement.